NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/14/2026
Back to search
Official data from USPTO
HUMABODY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000079332232Class
1, 5, 40, 42, 45
Filing
79332232
Registration
7064382
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
44
Latest update
05/15/2026
Trademark type
Combined
Nice classes
1, 5, 40, 42, 45
Filing date
08/12/2021
Registration date
05/30/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/30/2023
Last transaction
05/15/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
GB
Examiner
RILEY, KATHERINE M
Law office
M80
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "HUMABODY" in a stylized font.
Holders and representatives
Holders
Crescendo Biologics Limited
Representatives
Matthew L. Frisbee Leason Ellis LLP
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals used in industry and science; Chemicals for use in science and industrychemicals for laboratory research purposes; chemicals for use in science and industrychemicals for use in medical research; chemicals for use in science and industrychemicals for use in oncological research; antibodies and antibody fragments for scientific and laboratory use in the nature of biochemicalsmonoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; laboratory chemicalsantibody reagents used in cell and tissue assays for scientific and laboratory use; biochemicalsmonoclonal antibodies and antibody fragments for use in medical research; biochemicalsmonoclonal antibodies and antibody fragments for use in oncological research; molecules primarily comprised of antibodies and antibody fragments for use in medical research; molecules primarily comprised of antibodies and antibody fragments in the nature of biochemicalsmonoclonal antibodies and antibody fragments for use in oncological research; antibodies and antibody fragments all being proteins for industrial use in the discoverypreclinical developmentclinical development and manufacture of therapeutic products
Class 5
Pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; veterinary preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodiesbeing pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; antibody fragmentsbeing pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; therapeutic preparations that use monoclonal antibodiesnamely therapeutic pharmaceutical for treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseasesfor medical and veterinary diagnostics; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases for use in the discoverypreclinical and clinical development of therapeutic products for medical and veterinary purposes; pharmaceutical preparations for use in oncology; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases for use in oncology and therapeutic treatments in relation thereto
Class 40
Custom manufacture of chemicalsbiologicalsantibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments; custom manufacture of antibody and antibody fragmentsfor othersfor use in medical therapiesincluding in relation to oncology; consultancyadvice and information relating to all of the aforesaid services
Class 42
Scientific and technological servicesresearch and design in the field of chemicalsbiologicalsantibodies and antibody fragments; scientific laboratory research services relating to the development of antibodies and antibody fragments; oncological research; research into the development of antibodies and antibody fragments; scientific and technological servicesprovision of antibodies and antibody fragments for medical and veterinary research and development in the field of chemicalsbiologicalsantibodies and antibody fragments; engineering of antibodies and antibody fragments; scientific servicesdiscoverypreclinical and clinical development of therapeutic products; scientific research for others in the field of drug discoverypreclinical and clinical development of therapeutic and diagnostic products; research into antibodiesantibody fragments for others; research into the formationmanufacturemedical usage and manipulation of antibodies and antibody fragments for others; consultancyadvice and information relating to all of the aforesaid services
Class 45
Licensing of intellectual propertylicensing of research and development; licensing of intellectual propertylicensing of medical therapeutic research; licensing of intellectual propertylicensing of research relating to antibodies and antibody fragments; licensing of intellectual propertylicensing of research in relation to the formationmanufacturemedical usage and manipulation of antibodies and antibody fragments; consultancyadvice and information relating to all of the aforesaid services
Publications
History of USPTO decisions and trademark events.
44 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/17/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/17/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/17/2025
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
06/03/2025
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
11/08/2024
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
10/27/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/25/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/31/2023
FIMP
FINAL DISPOSITION PROCESSED
08/31/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/30/2023
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
08/19/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/30/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
05/30/2023
GPNX
NOTIFICATION PROCESSED BY IB
03/15/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/14/2023
PUBO
PUBLISHED FOR OPPOSITION
03/14/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/22/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/22/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/22/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/06/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
02/03/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/03/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
02/03/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/03/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
12/16/2022
GNFR
FINAL REFUSAL E-MAILED
12/16/2022
CNFR
FINAL REFUSAL WRITTEN
12/16/2022
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
11/15/2022
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
11/15/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/28/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/28/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/28/2022
CREV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
10/14/2022
RFNT
REFUSAL PROCESSED BY IB
07/13/2022
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
07/10/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/16/2022
RFRR
REFUSAL PROCESSED BY MPU
06/16/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/24/2022
CNRT
NON-FINAL ACTION WRITTEN
05/23/2022
DOCK
ASSIGNED TO EXAMINER
05/13/2022
MAFR
APPLICATION FILING RECEIPT MAILED
02/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/04/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/03/2022
Continuous trademark protection
Get notified about every new filing that threatens HUMABODY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.